Citi analyst Patrick Donnelly raised the firm’s price target on Hologic to $90 from $85 and keeps a Neutral rating on the shares. The company’s fiscal Q2 beat was primarily driven by an accelerated recovery in the Breast Health business, the analyst tells investors in a research note. The firm updated its model to reflect the beat.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on HOLX:
- Hologic raises FY23 EPS view to $3.75-$3.95 from $3.55-$3.85, consensus $3.75
- Hologic sees Q3 adjusted EPS 83c-93c, consensus 88c
- Hologic reports Q2 adjusted EPS $1.06, consensus 88c
- HOLX Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Hologic price target raised to $92 from $90 at Mizuho